Mueller-Hinton Agar: Composition, Uses, and Importance

Introduction: Mueller-Hinton Agar and the Global Fight Against Antimicrobial Resistance

Mueller-Hinton Agar (MHA) is the global gold-standard medium for antimicrobial susceptibility testing (AST) — the laboratory process that determines which antibiotics will effectively treat a bacterial infection and which will not. Developed in 1941 by bacteriologists John Howard Mueller and Jane Hinton at Harvard Medical School, the medium was originally intended as a protein-free culture medium for the primary isolation of pathogenic Neisseria species. Its exceptional performance in antibiotic diffusion assays quickly established it as the medium of choice for AST — a role it has held for over eight decades, and that has only grown in clinical importance as the global antimicrobial resistance (AMR) crisis has intensified.

The clinical relevance of MHA-based susceptibility testing cannot be overstated. The World Health Organization (WHO) has declared AMR one of the top ten global public health threats. A 2022 landmark study in The Lancet attributed 1.27 million deaths directly to bacterial AMR in 2019, with an additional 3.68 million deaths associated with AMR. Accurate AST on MHA — following CLSI or EUCAST standardized methodology — is the frontline tool that guides clinician prescribing decisions, identifies resistance patterns for surveillance, drives antibiotic stewardship programs, and underpins AMR research globally.

ContractLaboratory.com connects clinical microbiology laboratories, pharmaceutical companies, medical device manufacturers, and public health agencies with accredited microbiology and pathogen detection laboratories for antimicrobial susceptibility testing and related services. See also our guides to antimicrobial resistance testing and pathogen testing.

Mueller-Hinton Agar Composition: Ingredients and Their Functions

The composition of Mueller-Hinton Agar is defined by international standards and must be tightly controlled to ensure reproducible, reliable AST results. Variations in composition — particularly in divalent cation content, pH, thymidine content, and agar concentration — directly affect antibiotic diffusion and zone diameters. The CLSI M02 standard specifies the acceptable performance range, and commercial MHA manufacturers must demonstrate lot-to-lot consistency through quality testing before releasing batches for clinical use.

1. Beef Extract (Infusion from Beef, Typically 2 g/L)

Beef extract provides a complex mixture of water-soluble nutrients extracted from fresh lean beef — including peptides, amino acids, nucleotides, vitamins (particularly B vitamins), carbohydrates, and organic acids. It supplies essential growth factors that support the proliferation of a wide range of non-fastidious clinically important bacteria. The exact composition of beef extract varies between manufacturers and production lots, which is one source of batch-to-batch variability that must be controlled through quality specifications and lot-acceptance testing.

2. Casein Hydrolysate (Acid Hydrolysate of Casein, Typically 17.5 g/L)

Acid hydrolysis of casein (the primary protein in milk) produces a defined mixture of amino acids and short peptides that provide the primary nitrogen source for bacterial metabolism. Casein hydrolysate is a richer and more reproducible nitrogen source than beef extract alone. The combination of beef extract and casein hydrolysate provides a broad nutritional base that supports the growth of aerobic and facultatively anaerobic bacteria without supplementation — including the major clinically important genera (Staphylococcus, Streptococcus [non-fastidious strains], Enterococcus, Escherichia, Klebsiella, Pseudomonas, Acinetobacter, and others).

3. Starch (Typically 1.5 g/L) — Toxin Absorption and Thymidine Control

Starch in MHA serves two critical but distinct functions that are often underexplained:

• Toxic metabolite absorption: Starch acts as a colloid that adsorbs toxic fatty acids and metabolic byproducts that could inhibit bacterial growth or interfere with antibiotic diffusion, improving the reproducibility of zone diameters.
• PABA and thymidine/thymine reduction: Properly prepared MHA has very low concentrations of para-aminobenzoic acid (PABA) and thymidine/thymine. These compounds are critical to AST accuracy for two antibiotic classes: PABA is an antagonist of sulfonamide activity (sulfonamides compete with PABA for dihydropteroate synthase); elevated thymidine/thymine levels enable bacteria to bypass trimethoprim inhibition of dihydrofolate reductase through an alternative folate synthesis pathway. High thymidine content in MHA produces falsely small inhibition zones for trimethoprim and co-trimoxazole (trimethoprim-sulfamethoxazole), potentially misclassifying susceptible organisms as resistant. CLSI requires that MHA lots be tested for thymidine content and rejected if levels are too high. Starch hydrolysis to glucose also provides supplemental energy for bacterial growth.

4. Agar (Typically 17 g/L) — Solidification and Diffusion Matrix

Agar is the solidifying agent that creates the gel matrix through which antibiotics diffuse radially from impregnated disks. MHA is formulated as a “loose” agar (lower agar concentration relative to most bacteriological media), which produces a gel with lower tensile strength but superior antibiotic diffusion properties — larger, sharper-edged inhibition zones with better resolution. The agar concentration also determines the gel’s water content, which affects diffusion coefficient. Agar from different sources varies in mineral content, and manufacturers must use purified agar grades with controlled sulfate and mineral content.

5. pH 7.2–7.4 — Critical for Antibiotic Activity

MHA is adjusted and maintained at a final pH of 7.2–7.4 after autoclaving and before solidification. This narrow pH range is critical because antibiotic activity is pH-dependent for several important drug classes:

• Aminoglycosides (gentamicin, tobramycin, amikacin): More active at alkaline pH (>7.4). Reduced activity at pH < 7.2.
• Tetracyclines: More active at acidic to neutral pH; activity decreases at alkaline pH.
• Macrolides (erythromycin, azithromycin, clarithromycin): Substantially more active at alkaline pH; a single pH unit change can alter MIC by 4-fold or more for macrolides against some organisms.
• Nitrofurantoin: More active at acidic pH.

MHA lots with pH outside the 7.2–7.4 specification must be rejected. CLSI specifies that pH should be checked after the medium has cooled to room temperature, using a surface pH electrode or by dipping a calibrated pH probe directly into freshly poured plates.

6. Divalent Cations: Calcium (Ca²⁺) and Magnesium (Mg²⁺)

MHA contains controlled concentrations of calcium and magnesium ions — a parameter that receives insufficient attention in many laboratory guides. CLSI specifies that MHA for disk diffusion should have Ca²⁺ approximately 25 mg/L and Mg²⁺ approximately 12.5 mg/L. The clinical significance is profound:

• Aminoglycoside activity against Pseudomonas aeruginosa: Ca²⁺ and Mg²⁺ competitively displace aminoglycosides (gentamicin, tobramycin) from their anionic binding sites on lipopolysaccharide (LPS) on the outer membrane of Pseudomonas aeruginosa. Elevated divalent cation concentrations reduce aminoglycoside uptake into the cell, producing falsely elevated MICs and falsely small disk diffusion zones. This is why divalent cation control is most critical for aminoglycoside testing against P. aeruginosa.
• CAMHB specification: The liquid form, Cation-Adjusted Mueller-Hinton Broth (CAMHB), has even tighter specifications for MIC testing: Ca²⁺ 20–25 mg/L and Mg²⁺ 10–12.5 mg/L, verified by atomic absorption spectrophotometry or ICP. See the CAMHB section below.

Regulatory Standards Governing MHA Use: CLSI and EUCAST

CLSI Standards for Disk Diffusion and MIC Testing

The Clinical and Laboratory Standards Institute (CLSI) publishes the principal North American standards governing MHA-based AST. Three documents are central:

• CLSI M02 — Performance Standards for Antimicrobial Disk Susceptibility Tests: Defines the Kirby-Bauer disk diffusion methodology — MHA preparation requirements (4 mm depth, pH 7.2–7.4, lot acceptance criteria), inoculum standardization (McFarland 0.5), disk placement (no more than 12 disks per 150 mm plate; no more than 5 per 100 mm plate), incubation conditions (35 ± 2°C, 16–18 hours for most organisms), and zone measurement. Updated periodically.
• CLSI M07 — Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Defines broth microdilution (BMD) in Cation-Adjusted Mueller-Hinton Broth (CAMHB) as the reference method for MIC determination. 12th edition published 2024. MIC is the fundamental pharmacodynamic parameter that underpins all susceptibility category assignments.
• CLSI M100 — Performance Standards for Antimicrobial Susceptibility Testing: Published annually (the most frequently updated CLSI standard), M100 provides the zone diameter and MIC breakpoints for interpretation of disk diffusion and dilution test results as Susceptible (S), Susceptible-Increased Exposure (SDD) or Intermediate (I), or Resistant (R). New drugs, new resistant mechanisms, and epidemiological breakpoint updates are incorporated into each edition. M100 also contains quality control (QC) target ranges for reference strains.

EUCAST Standards for Disk Diffusion and MIC Testing

The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is the European counterpart to CLSI, and is adopted by all EU/EEA member states, the WHO Global Antimicrobial Resistance Surveillance System (GLASS), and many countries globally. EUCAST also uses MHA for disk diffusion, but with important methodological differences:

Methodological aspect	CLSI	EUCAST
Base medium	Mueller-Hinton Agar (same specification)	Mueller-Hinton Agar (same base specification)
Blood supplement (fastidious organisms)	5% sheep blood (defibrinated) for Streptococcus spp., Campylobacter, some others	5% horse blood + lysed horse blood (0.4% NAD/chocolate agar for some); 5% horse blood for Streptococcus spp.
Incubation temperature	35 ± 2°C (range 33–37°C)	35 ± 1°C (narrower tolerance)
Incubation duration (non-fastidious)	16–18 h for Enterobacterales, Staphylococcus, P. aeruginosa; 20–24 h for most others	16–20 h (unified)
Disk contents	Vary; 13 antimicrobial agents use different disk contents vs EUCAST	Vary; standardized across Europe; 13 agents differ from CLSI disks
Susceptibility categories	S (Susceptible), SDD (Susceptible-Dose Dependent), I (Intermediate), R (Resistant)	S (Susceptible, standard dosing), I (Susceptible, increased exposure), R (Resistant). I replaces “Intermediate” with clinical guidance for higher-dose prescribing.
Breakpoint basis	MIC + PK/PD data + clinical outcome data	MIC + epidemiological cutoff (ECOFF) + PK/PD + clinical data
Update frequency	M100 updated annually (January)	Breakpoint tables updated annually (January)

Because CLSI and EUCAST use different zone diameter breakpoints for many drug-organism combinations, the same disk diffusion result can yield different susceptibility category assignments depending on which guidelines are applied. Laboratories must specify which guidelines they follow and apply them consistently. For AMR surveillance reporting to international databases, EUCAST breakpoints are often required (WHO GLASS program).

Kirby-Bauer Disk Diffusion: Method and Procedural Requirements

The Kirby-Bauer disk diffusion method, formalized by Bauer, Kirby, Sherris, and Turck in 1966 and standardized through CLSI M02, is the most widely performed AST method in the world. Its simplicity, low cost, flexibility, and visual interpretability make it indispensable in clinical microbiology laboratories from reference centers to resource-limited settings. The method is performed on MHA plates following strict procedural requirements that directly affect the validity of results.

Step-by-Step Procedure

• Plate preparation — 4 mm depth: MHA plates must be poured to a depth of exactly 4 mm. Thinner plates produce excessively large inhibition zones (falsely susceptible results); thicker plates produce excessively small zones (falsely resistant results). A standard 90 mm (150 mm for larger formats) Petri dish filled to 4 mm depth requires approximately 25 mL (or 60–70 mL for 150 mm plates). Plates must be stored at 2–8°C until use and equilibrated to room temperature before inoculation. pH check must confirm 7.2–7.4. The agar surface must be moist but free from surface water.
• Inoculum preparation — McFarland 0.5 turbidity standard: Three to five well-isolated colonies of the test organism from overnight non-selective agar are inoculated into nutrient broth (Mueller-Hinton broth or tryptic soy broth) and adjusted to a turbidity visually matching the McFarland 0.5 turbidity standard (equivalent to approximately 1–2 × 10⁸ CFU/mL). McFarland 0.5 corresponds to a barium sulfate suspension prepared by mixing 0.5 mL of 1.175% BaCl₂ with 99.5 mL of 1% H₂SO₄, or a calibrated latex bead standard. Turbidity is confirmed spectrophotometrically at 625 nm (absorbance 0.08–0.13). An inoculum that is too light produces large zones (false susceptibility); too heavy produces small zones (false resistance).
• Plate inoculation — lawn seeding: A sterile swab is dipped into the adjusted bacterial suspension, excess moisture removed by rotating against the tube wall, and the plate inoculated by swabbing uniformly in three directions (rotating the plate 60° each time) to produce a confluent lawn of bacterial growth across the entire agar surface. The inoculated plate must be allowed to dry for 3–5 minutes at room temperature before disk application.
• Disk placement: Antibiotic-impregnated paper disks are placed on the inoculated agar surface within 15 minutes of inoculation using a sterile forceps or disk dispenser. Each disk must be pressed firmly to ensure complete contact with the agar surface. No more than 12 disks per 150 mm plate and 5 disks per 100 mm plate (CLSI guidelines) to prevent zone overlap. Disk placement is irreversible once the disk contacts the agar — antibiotic begins diffusing immediately.
• Incubation: Inverted plates are incubated at 35 ± 2°C (CLSI) or 35 ± 1°C (EUCAST) for 16–18 hours for most non-fastidious organisms. Longer incubation (24 hours) may be required for some slow-growing organisms or specific drug-organism combinations (e.g., oxacillin/methicillin resistance in Staphylococcus aureus requires 24 hours at 33–35°C). CO₂ incubation (5–7%) is used for Streptococcus pneumoniae and some fastidious organisms.
• Zone measurement and interpretation: Inhibition zone diameters are measured to the nearest millimeter using a ruler or calipers from the back of the plate against a dark background. The zone edge is defined as the point of complete inhibition of visible growth. Zone diameters are compared against the published breakpoints in CLSI M100 (or EUCAST breakpoint tables) to classify the organism as S (Susceptible), I (Intermediate/Susceptible-Increased Exposure), or R (Resistant) to each antibiotic tested. Larger zones = lower MIC = more susceptible.

Quality Control: Reference Strains for MHA Validation

Every batch of MHA used for AST must be validated using reference strains with known, expected zone diameter or MIC ranges. If QC results fall outside the acceptable range, the medium lot must be rejected. CLSI M100 and EUCAST both specify QC reference strains and acceptable ranges (updated annually). The primary QC strains for disk diffusion on MHA are:

• Staphylococcus aureus ATCC 25923: The primary QC strain for disk diffusion against most antibiotics. A well-characterized susceptible S. aureus strain producing predictable zone diameters across the antibiotic panel.
• Escherichia coli ATCC 25922: Primary QC strain for Gram-negative disk diffusion, particularly for beta-lactams and aminoglycosides.
• Pseudomonas aeruginosa ATCC 27853: Used for aminoglycoside and anti-pseudomonal antibiotic QC. Critical for validating divalent cation concentrations in MHA, as P. aeruginosa aminoglycoside zones are especially sensitive to Ca²⁺/Mg²⁺ levels.
• Escherichia coli ATCC 35218: Used for QC of beta-lactam/beta-lactamase inhibitor combinations (ampicillin-sulbactam, amoxicillin-clavulanate) — it carries a beta-lactamase that allows testing of inhibitor combinations.
• Haemophilus influenzae ATCC 49247 and ATCC 49766: Used for QC on MHA supplemented with 5% sheep blood + Haemophilus Test Medium supplement (CLSI) or 5% horse blood (EUCAST) for fastidious organism testing.

Beyond Disk Diffusion: CAMHB for MIC Testing and the E-Test

Cation-Adjusted Mueller-Hinton Broth (CAMHB) and Broth Microdilution

While disk diffusion on solid MHA is the most widely performed AST method globally, the reference method — the gold standard against which all other AST methods are calibrated — is broth microdilution (BMD) in Cation-Adjusted Mueller-Hinton Broth (CAMHB), as defined by CLSI M07 (12th edition, 2024) and ISO 20776-1.

CAMHB is prepared from standard Mueller-Hinton broth with precise supplementation of divalent cations: Ca²⁺ 20–25 mg/L and Mg²⁺ 10–12.5 mg/L. Divalent cation concentrations are verified by atomic absorption spectrophotometry or ICP-OES and adjusted (by addition of CaCl₂ and MgCl₂ solutions) to within specification before use. Improperly adjusted CAMHB is a major source of inter-laboratory MIC variability, particularly for aminoglycosides against P. aeruginosa.

In broth microdilution, serial two-fold dilutions of antibiotic are prepared in CAMHB in the wells of a 96-well microtiter plate (typical concentration range covering 8–12 two-fold steps). Each well is inoculated with a standardized bacterial suspension (~5 × 10⁵ CFU/mL, approximately 1:200 dilution of a McFarland 0.5 suspension). After 16–20 hours incubation at 35°C, wells are examined for visible turbidity. The Minimum Inhibitory Concentration (MIC) is the lowest antibiotic concentration that completely prevents visible bacterial growth. MIC values in mg/L (or μg/mL) are compared against CLSI M100 or EUCAST breakpoints to assign S/I/R categories. Because MIC is a continuous variable and disk diffusion zone size is a surrogate, MIC determination by BMD is the pharmacodynamically definitive method for guiding treatment in complex cases.

E-Test (Epsilometer Test) — Gradient Diffusion on MHA

The E-test (originally by AB Biodisk, now manufactured by bioMérieux) is a commercially available gradient diffusion strip that combines the simplicity of disk diffusion with the quantitative MIC output of broth microdilution, performed directly on MHA plates.

An E-test strip is a thin plastic carrier approximately 5 mm × 50 mm, impregnated on one side with a continuous exponential gradient of antibiotic spanning 15 two-fold serial dilutions (e.g., 0.016–256 mg/L for a given antibiotic). The other side carries a printed numerical MIC scale. When placed on a MHA plate inoculated with the test organism (McFarland 0.5 lawn, same as Kirby-Bauer), antibiotic diffuses from the strip into the agar, establishing a stable concentration gradient. After 16–18 hours incubation, a teardrop- or ellipse-shaped zone of inhibition forms around the strip. The MIC is read directly where the elliptical inhibition zone intersects the MIC scale on the strip.

The E-test is used clinically when: (1) a quantitative MIC is needed but full broth microdilution is not available or practical; (2) MIC determination is required for a specific drug-organism combination not included in commercial BMD panels; or (3) confirmation of borderline disk diffusion results is needed. E-test MICs correlate well with BMD MICs for most drug-organism combinations, though some systematic biases exist for specific drugs.

Mueller-Hinton Agar Variants for Fastidious Organisms

Fastidious bacteria — those with complex nutritional requirements that do not grow adequately on plain MHA — require supplemented formulations for AST:

• MHA + 5% sheep blood (CLSI): Used for AST of Streptococcus pneumoniae, other Streptococcus spp. (including S. pyogenes, S. agalactiae), and Campylobacter jejuni/coli (at 42°C, microaerophilic incubation). The addition of 5% defibrinated sheep blood provides hemin and NAD for streptococcal growth. For S. pneumoniae and viridans group streptococci, incubation is at 35°C in 5% CO₂ for 20–24 hours.
• MHA + 5% horse blood (EUCAST): EUCAST uses 5% horse blood (not sheep blood) for fastidious organism testing, as horse blood produces less hemolysis and provides a clearer medium for zone reading. For some organisms (H. influenzae, N. gonorrhoeae), EUCAST uses chocolate agar prepared on an MHA base with lysed horse blood and NAD supplement.
• Mueller-Hinton Fastidious Agar (MH-F): Introduced in CLSI M100 as an alternative formulation for fastidious organisms, replacing the need for two different supplemented agar formulations. MH-F is an MHA base supplemented with 5% horse blood and has been validated for disk diffusion of H. influenzae, S. pneumoniae, and other fastidious species.
• Haemophilus Test Medium (HTM): A supplemented medium (MHA base + bovine hematin + yeast extract + NAD) used specifically for AST of Haemophilus influenzae under CLSI methodology. Note: EUCAST recommends chocolate MHA for H. influenzae.
• MHA + 2% NaCl: Used for detection of oxacillin/methicillin resistance in Staphylococci (particularly coagulase-negative staphylococci) — the elevated sodium chloride concentration potentiates expression of the mecA-encoded penicillin-binding protein PBP2a, improving detection sensitivity for MRSA/MRSE.

Mueller-Hinton Agar in the Context of Global Antimicrobial Resistance

The global AMR crisis places Mueller-Hinton Agar and the AST systems it underpins at the center of one of medicine’s most urgent challenges. The WHO Critical Priority Pathogens list — carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, and carbapenem-resistant / ESBL-producing Enterobacterales (Klebsiella pneumoniae, E. coli) — are routinely tested on MHA. The ESKAPE organisms (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp.) represent the pathogens responsible for the majority of hospital-acquired infections with limited treatment options.

Accurate MHA-based AST using validated CLSI or EUCAST methodology is foundational to: (1) Clinical decision-making — prescribing the correct antibiotic at the correct dose for individual patients; (2) Antibiotic stewardship programs — reducing unnecessary broad-spectrum antibiotic use to slow resistance development; (3) AMR surveillance — feeding data to national and global surveillance networks (WHO GLASS, ECDC EARS-Net, CDC SENTRY) that track resistance trends; and (4) New antibiotic development — MHA-based MIC testing is the primary screening assay used by pharmaceutical companies and academic research groups to evaluate the activity of new antimicrobial candidates.

ContractLaboratory.com connects pharmaceutical companies, clinical laboratories, and public health agencies with specialized antimicrobial resistance testing laboratories and microbiology testing services for AMR surveillance, susceptibility testing, and antimicrobial development support.

Why MHA Is the Gold Standard: Advantages and Limitations

Why CLSI Selected Mueller-Hinton Agar

CLSI formally selected MHA as the standard disk diffusion medium based on six specific characteristics:

• Good batch-to-batch reproducibility — the most important selection criterion for a standardized test.
• Low in sulfonamide, trimethoprim, and tetracycline inhibitors — minimizing false resistance for these drug classes.
• Low levels of thymidine and thymine — preventing antagonism of trimethoprim activity.
• Support for satisfactory growth of most non-fastidious pathogens — without supplementation.
• Excellent antibiotic diffusion properties — resulting in sharp, well-defined inhibition zone edges.
• Large body of supporting data — decades of published zone diameter standards and clinical correlation data.

Limitations

• Fastidious organisms require supplementation: Streptococcus pneumoniae, Haemophilus influenzae, Neisseria gonorrhoeae, Neisseria meningitidis, Helicobacter pylori, anaerobes, and obligate intracellular organisms (Chlamydia, Mycoplasma) all require modified media, different atmospheric conditions, or different testing methodologies.
• Not suitable for anaerobes: Anaerobic susceptibility testing requires specific media (Brucella agar with blood and vitamin K/hemin) and anaerobic atmospheric conditions.
• Not validated for all antibiotic classes: Daptomycin testing requires Ca²⁺ supplementation of CAMHB (50 mg/L final concentration) and is not reliably tested by disk diffusion on standard MHA. Polymyxins (colistin, polymyxin B) show poor correlation between disk diffusion zone diameters and MICs — broth microdilution is strongly preferred for polymyxins.
• Requires strict procedural adherence: Variables including plate depth, inoculum turbidity, incubation temperature and duration, disk placement timing, and medium pH all affect results. Deviations produce unreliable zone diameters and potentially incorrect susceptibility categorizations with direct patient safety implications.

Finding Accredited Antimicrobial Susceptibility Testing Laboratories

AST for clinical, pharmaceutical, and research applications requires ISO/IEC 17025-accredited or CLIA-certified laboratories with validated methods, appropriate QC programs, and documented performance against reference strains. For pharmaceutical antibiotic development and regulatory submissions (FDA, EMA), GLP-compliant MIC testing programs may be required. For clinical diagnostic laboratories, proficiency testing through CAP (College of American Pathologists) or equivalent programs is essential.

ContractLaboratory.com connects clinical laboratories, pharmaceutical companies, veterinary testing facilities, food safety laboratories, and academic research teams with accredited microbiology and pathogen detection laboratories for Kirby-Bauer disk diffusion, broth microdilution MIC testing, and antimicrobial resistance characterization. See also our specialized resource on antimicrobial resistance testing, our pathogen testing guide, and microbiology challenge testing.

Frequently Asked Questions About Mueller-Hinton Agar

Conclusion

Mueller-Hinton Agar remains the cornerstone of antimicrobial susceptibility testing more than 80 years after its development — a testament to its uniquely well-balanced properties for antibiotic diffusion, bacterial growth support, and analytical reproducibility. Understanding its composition in depth — the functional roles of starch in PABA/thymidine reduction, the critical importance of Ca²⁺/Mg²⁺ control for aminoglycoside accuracy, the significance of the 4 mm depth requirement and McFarland 0.5 inoculum — is essential for any laboratory professional performing disk diffusion testing. The governing standards (CLSI M02, M07, M100; EUCAST breakpoint tables) and the complementary methods they govern — Kirby-Bauer disk diffusion, broth microdilution MIC testing in CAMHB, and E-test gradient diffusion — form the integrated toolkit for accurate antimicrobial susceptibility determination. In the context of the global AMR crisis, the accurate and standardized use of MHA has never been more clinically consequential.

ContractLaboratory.com connects clinical laboratories, pharmaceutical and veterinary companies, and research institutions with accredited microbiology and pathogen detection laboratories for all forms of antimicrobial susceptibility testing. Submit a testing request or contact our team.